查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗生素抗性市场全球市场:治疗药，病原体，治疗各类型 - 情形分析，执行投资者指南附着(2023年～2027年)
市场调查报告书
商品编码
1309758

抗生素抗性市场全球市场:治疗药，病原体，治疗各类型 - 情形分析，执行投资者指南附着(2023年～2027年)

Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive and Investor Guides. 2023 to 2027
出版日期: | 出版商: Howe Sound Research | 英文 449 Pages | 商品交期: 最快1-2个工作天内

价格

本报告提供全球抗生素抗性市场相关调查，提供市场概要，以及病原体，治疗各类型趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场指南

第2章 简介和市场定义

第3章 市场动态概要

  • 市场参与企业- 作用及影响
    • 製药厂商- 大/医药品
    • 製药厂商- 非专利
    • CRO，CMO
    • 体外诊断产业
    • 医药品销售公司
    • 生物科技企业
    • 法规机关
  • 了解抗菌素耐药性
  • 新抗生素和技术的变革之路
  • 诊断在 AMR 中的关键作用

第4章 AMR的市场机会

  • AMR的主要市场机会
  • 治疗技术开发机会

第5章 抗生素抗性的最近趋势

第6章 主要生物科技企业和那个技术

  • Melinta Therapeutics
  • Arsanis
  • Phage Technologies S.A
  • Westway Health
  • Tetraphase Pharmaceuticals
  • BioVersys GmbH
  • Nabriva Therapeutics
  • Macrolide Pharmaceuticals
  • Nemesis Bioscience
  • C3J Therapeutics, Inc
  • EpiBiome
  • discuva
  • SmartPhage
  • AmpliPhi Biosciences
  • Pherecydes Pharma
  • Micreos
  • Procarta Biosystems
  • Lumavita
  • Madam Therapeutics
  • Priaxon
  • Biolytx Pharmaceuticals
  • AntibioTx
  • Xellia Pharmaceutials
  • Paratek Pharmaceuticals
  • Synereca Pharmaceuticals
  • Allecra Therapeutics
  • Fixed Phage
  • Enanta Pharmaceuticals, Inc.
  • Demuris
  • Prommune
  • Biosergen
  • Innovation Pharmaceuticals
  • Aviragen Therapeutics
  • Achillion Pharmaceuticals
  • ImmunNovative Developments，SL
  • ImmunNovative Developments, S.L.
  • Achaogen, Inc.
  • SelectX Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • Theravance Biopharma
  • Abbvie
  • KYORIN Pharmaceutical Co.,Ltd.
  • Iterum Therapeutics Limited
  • Forge Therapeutics
  • Alopexx Vaccine LLC
  • Integrated Biotherapeutics
  • Hennepin Life Sciences
  • Fedora Pharmaceuticals Inc.
  • Contrafect Corporation
  • Basilea Pharmaceutica Ltd.
  • AiCuris
  • RedHill Biopharma
  • Redx Pharma Plc/Redx Anti Infectives Ltd.
  • ABAC Therapeutics
  • Alaxia SAS
  • Antabio S.A.S
  • Auspherix Ltd
  • BioFilm Pharma
  • Centauri Therapeutics Ltd
  • Combioxin SA
  • Da Volterra
  • Debiopharm International SA
  • Deinobiotics/Deinove
  • Destiny Pharma plc
  • Eligo Bioscience
  • Helperby Therapeutics Ltd
  • Karveel Pharmaceuticals
  • MaaT Pharma
  • Motif BioSciences, Inc/Motif Bio PLC
  • Mutabilis SAS
  • Neem Biotech Ltd
  • Northern Antibiotics Oy (Ltd)
  • Nosopharm
  • NovaBiotics Ltd
  • Phico Therapeutics Ltd
  • Polyphor Ltd
  • QureTech Bio AB
  • SetLance srl
  • Ultupharma AB
  • Vaxdyn
  • Vibiosphen
  • Bioaster
  • Vivexia
  • KBP Biosciences
  • Absynth Biologics
  • Spero Therapeutics
  • Merck
  • Symphogen
  • Warp Drive Bio
  • Johnson & Johnson (Janssen)
  • Allergan
  • GlaxoSmithKline
  • Novartis
  • Gilead Sciences
  • AstraZeneca
  • Sanofi
  • Shionogi Inc.
  • Cipla
  • DSM Sinochem Pharmaceuticals
  • Wockhardt Ltd.
  • VenatoRx Pharmaceuticals
  • MicuRx
  • Entasis Therapeutics
  • Merlion Pharmaceuticals
  • Aridis Pharmaceuticals Inc.

第7章 全球市场规模

  • 各国全球市场
  • 病原体的全球市场
  • 各技术的全球市场

第8章 病原体的市场规模

第9章 各技术的市场规模

第10章 AMR的未来

第11章 附录

OVERVIEW:

Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Strategic Situation Analysis
  • 1.2 Guide for Executives and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Antimicrobial Resistance
  • 2.2 Defining the Opportunity
    • 2.2.1 Revenue Market Size
  • 2.3 Methodology
    • 2.3.1 Methodology
    • 2.3.2 Sources
    • 2.3.3 Authors
  • 2.4 U.S. Antibiotic Markets - Perspective
    • 2.4.1 U.S. Outpatient Use of Antibiotics
    • 2.4.2 U.S. Pharmaceutical Spending

3 Overview of a Dynamic Market

  • 3.1 Market Players - Roles & Impacts
    • 3.1.1 Drug manufacturers - Larger/pharmaceutical
    • 3.1.2 Drug manufacturers - Generic
    • 3.1.3 Contract Research and Manufacturing
    • 3.1.4 In Vitro Diagnostics Industry
    • 3.1.5 Drug Marketing Companies
    • 3.1.6 Biotechnology Companies
    • 3.1.7 Regulatory Bodies
  • 3.2 Understanding Antimicrobial Resistance
    • 3.2.1 What is Antimicrobial Resistance (AMR)
    • 3.2.2 Bacteria and Other Microbes
    • 3.2.3 The History of Antibiotics
    • 3.2.4 The Role of Animal Husbandry
    • 3.2.5 The Implications of Horizontal Transfer
    • 3.2.6 The Threat of AMR
  • 3.3 The Changing Road to New Antibiotics & Technologies
  • 3.4 The Key Role of Diagnostics in AMR

4 The Market Opportunity of AMR

  • 4.1 The Key Large Market Opportunities in AMR
    • 4.1.1 Streptococcus Pneumoniae (DRSP)
    • 4.1.2 Campylobacter (DRC)
    • 4.1.3 Clostridium Difficile (CD)
    • 4.1.4 Staphylococcus aureus (MRSA)
    • 4.1.5 Neisseria gonorrhoeae (DRNG)
    • 4.1.6 Salmonella (DRNTS)
  • 4.2 Therapeutic Technology Development Opportunities
    • 4.2.1 Using Viruses Against Bacteria
    • 4.2.2 Hydrolytic Enzymes Join the Fight
    • 4.2.3 Antibodies
    • 4.2.4 Vaccines
    • 4.2.5 Probiotic Technology
    • 4.2.6 Peptides vs. Pathogens
    • 4.2.7 Mining Obsolete Science
    • 4.2.8 CRISPR Antibiotics

5 Antibiotic Resistance Recent Developments

  • 5.1.1 Recent Developments - Importance and How to Use This Section
  • 5.1.2 Importance of These Developments
  • 5.1.3 How to Use This Section
  • 5.2 Bacteriophage May Combat AMR
  • 5.3 Shionogi to Acquire Qpex Biopharma
  • 5.4 Adaptive Phage Therapeutics to Fight Antibiotic Resistance
  • 5.5 Smartbax to create next-generation antibiotics
  • 5.6 Startup Solu raises €1M to combat AMR
  • 5.7 Akthelia Pharma and University of Iceland to Combat AMR
  • 5.8 WHO warns of too few new Antibiotics
  • 5.9 Bactobio Raises £6 Million To Discover Novel Antimicrobials
  • 5.10 AMR triggers race to develop phages
  • 5.11 AMR Pandemic Overlooked
  • 5.12 New resistance-busting antibiotic combination
  • 5.13 CDC Awards $22M to Combat Antimicrobial Resistance
  • 5.14 Antibiotic resistance outwitted by supercomputers
  • 5.15 STIs Reach Record Highs
  • 5.16 New research using nanoparticles to bolster waning antibiotics
  • 5.17 OpGen Receives FDA Clearance for AMR Panel
  • 5.18 CDC Updates STI Diagnosis, Treatment Guidelines
  • 5.19 Positive associations between AM use in animals and AMR in humans
  • 5.20 PEW Antibiotic Pipeline Findings

6 Key Biotechnology Companies and Their Technology

  • 6.1 Melinta Therapeutics
  • 6.2 Arsanis
  • 6.3 Phage Technologies S.A
  • 6.4 Westway Health
  • 6.5 Tetraphase Pharmaceuticals
  • 6.6 BioVersys GmbH
  • 6.7 Nabriva Therapeutics
  • 6.8 Macrolide Pharmaceuticals
  • 6.9 Nemesis Bioscience
  • 6.10 C3J Therapeutics, Inc
  • 6.11 EpiBiome
  • 6.12 discuva
  • 6.13 SmartPhage
  • 6.14 AmpliPhi Biosciences
  • 6.15 Pherecydes Pharma
  • 6.16 Micreos
  • 6.17 Procarta Biosystems
  • 6.18 Lumavita
  • 6.19 Madam Therapeutics
  • 6.20 Priaxon
  • 6.21 Biolytx Pharmaceuticals
  • 6.22 AntibioTx
  • 6.23 Xellia Pharmaceutials
  • 6.24 Paratek Pharmaceuticals
  • 6.25 Synereca Pharmaceuticals
  • 6.26 Allecra Therapeutics
  • 6.27 Fixed Phage
  • 6.28 Enanta Pharmaceuticals, Inc.
  • 6.29 Demuris
  • 6.30 Prommune
  • 6.31 Biosergen
  • 6.32 Innovation Pharmaceuticals
  • 6.33 Aviragen Therapeutics
  • 6.34 Achillion Pharmaceuticals
  • 6.35 ImmunNovative Developments, S.L.
  • 6.36 Achaogen, Inc.
  • 6.37 SelectX Pharmaceuticals, Inc.
  • 6.38 TaiGen Biotechnology Co., Ltd.
  • 6.39 Theravance Biopharma
  • 6.40 Abbvie
  • 6.41 KYORIN Pharmaceutical Co.,Ltd.
  • 6.42 Iterum Therapeutics Limited
  • 6.43 Forge Therapeutics
  • 6.44 Alopexx Vaccine LLC
  • 6.45 Integrated Biotherapeutics
  • 6.46 Hennepin Life Sciences
  • 6.47 Fedora Pharmaceuticals Inc.
  • 6.48 Contrafect Corporation
  • 6.49 Basilea Pharmaceutica Ltd.
  • 6.50 AiCuris
  • 6.51 RedHill Biopharma
  • 6.52 Redx Pharma Plc/ Redx Anti Infectives Ltd.
  • 6.53 ABAC Therapeutics
  • 6.54 Alaxia SAS
  • 6.55 Antabio S.A.S
  • 6.56 Auspherix Ltd
  • 6.57 BioFilm Pharma
  • 6.58 Centauri Therapeutics Ltd
  • 6.59 Combioxin SA
  • 6.60 Da Volterra
  • 6.61 Debiopharm International SA
  • 6.62 Deinobiotics/Deinove
  • 6.63 Destiny Pharma plc
  • 6.64 Eligo Bioscience
  • 6.65 Helperby Therapeutics Ltd
  • 6.66 Karveel Pharmaceuticals
  • 6.67 MaaT Pharma
  • 6.68 Motif BioSciences, Inc / Motif Bio PLC
  • 6.69 Mutabilis SAS
  • 6.70 Neem Biotech Ltd
  • 6.71 Northern Antibiotics Oy (Ltd)
  • 6.72 Nosopharm
  • 6.73 NovaBiotics Ltd
  • 6.74 Phico Therapeutics Ltd
  • 6.75 Polyphor Ltd
  • 6.76 QureTech Bio AB
  • 6.77 SetLance srl
  • 6.78 Ultupharma AB
  • 6.79 Vaxdyn
  • 6.80 Vibiosphen
  • 6.81 Bioaster
  • 6.82 Vivexia
  • 6.83 KBP Biosciences
  • 6.84 Absynth Biologics
  • 6.85 Spero Therapeutics
  • 6.86 Merck
  • 6.87 Symphogen
  • 6.88 Warp Drive Bio
  • 6.89 Johnson & Johnson (Janssen)
  • 6.90 Pfizer
  • 6.91 Allergan
  • 6.92 GlaxoSmithKline
  • 6.93 Novartis
  • 6.94 Gilead Sciences
  • 6.95 AstraZeneca
  • 6.96 Sanofi
  • 6.97 Shionogi Inc.
  • 6.98 Cipla
  • 6.99 DSM Sinochem Pharmaceuticals
  • 6.100 Wockhardt Ltd.
  • 6.101 VenatoRx Pharmaceuticals
  • 6.102 MicuRx
  • 6.103 Entasis Therapeutics
  • 6.104 Merlion Pharmaceuticals
  • 6.105 Aridis Pharmaceuticals Inc.
  • 6.106 The Therapeutics Race - Summary of Companies Research
  • Areas

7 Global Market Size

  • 7.1 Global Market by Country
  • 7.2 Global Market by Pathogen
  • 7.3 Global Market by Technology

8 Market Sizes by Pathogen

  • 8.1 DRSP Market
  • 8.2 DRC Market
  • 8.3 CD Market
  • 8.4 MRSA Market
  • 8.5 DRNG Market
  • 8.6 DRNTS Market
  • 8.7 Other Pathogen Market

9 Market Sizes by Technology

  • 9.1 Antibiotics Market
  • 9.2 Phage Market
  • 9.3 Pep/Lys Market
  • 9.4 Antibodies Market
  • 9.5 Vaccine Market
  • 9.6 Other Technology Market

10 The Future of AMR

11 Appendices

  • 11.1 United States Medicare System: Top Selling Drugs 2011-2015

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Therapeutic
  • Table 7 - Market Potential DRC Therapeutic
  • Table 8 Eight Technologies under development
  • Table 9 Antibodies Approved for Infectious Disease Treatment
  • Table 10 Therapeutic Technology Research - # of Companies
  • Table 11 Global Market by Country
  • Table 12 Global Market by Pathogen
  • Table 13 Global Market by Technology
  • Table 14 DRSP Segment by Country
  • Table 15 DRC Segment by Country
  • Table 16 CD Segment by Country
  • Table 17 MRSA Segment by Country
  • Table 18 DRNG Segment by Country
  • Table 19 DRNTS Segment by Country
  • Table 20 Other Pathogen Segment by Country
  • Table 21 Antibiotics Segment by Country
  • Table 22 Phage Segment by Country
  • Table 23 Pep/Lys Segment by Country
  • Table 24 Antibodies Segment by Country
  • Table 25 Vaccine Segment by Country
  • Table 26 Other Technology Segment by Country
  • Table 27 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1 Pharmaceutical Spending Trends
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 Phage T4 Anatomy and Infection Cycle
  • Figure 5 Key Global Markets
  • Figure 6 Pathogen Share by Year
  • Figure 7 Pathogen Segment Growth Rates
  • Figure 8 Segment Share Shifts
  • Figure 9 Market Share Start Year
  • Figure 10 Market Share End Year
  • Figure 11 Technology Share by Year
  • Figure 12 Pathogen Segment Growth Rates
  • Figure 13 Segment Share Shifts
  • Figure 14 Market Share Start Year
  • Figure 15 Market Share End Year
  • Figure 16 DRSP vs. Total Market Growth
  • Figure 17 DRC vs. Total Market Growth
  • Figure 18 CD vs. Total Market Growth
  • Figure 19 MRSA vs. Total Market Growth
  • Figure 20 DRNG vs. Total Market Growth
  • Figure 21 DRNTS vs. Total Market Growth
  • Figure 22 Other Pathogen vs. Total Market Growth
  • Figure 23 Antibiotics vs. Total Market Growth
  • Figure 24 Phage vs. Total Market Growth
  • Figure 25 Pep/Lys vs. Total Market Growth
  • Figure 26 Antibodies vs. Total Market Growth
  • Figure 27 Vaccine vs. Total Market Growth
  • Figure 28 Other Technology vs. Total Market Growth